Ajooni Biotech Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
AJOONI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ajooni Biotech has submitted the yearly disclosure required under Regulation 31(4) of SEBI's Substantial Acquisition of Shares and Takeovers Regulations for the financial year ended March 31, 2025. The promoters, along with persons acting in concert, have confirmed that they have not created any encumbrance (such as pledge, lien, or charge) on their shares, directly or indirectly, during the year. This is a routine annual compliance filing confirming that the promoter shareholding remains free of any encumbrance as of March 31, 2025. The disclosure was signed by promoter Jasjot Singh and submitted to NSE on April 2, 2025.
This is a neutral, routine compliance filing. It reassures shareholders that promoters have not pledged their holdings, which means no margin call or forced-sale risk from the promoter side during the year. No material impact on stock price is expected.